Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Janelle M. Meyer

Hematology Oncology | Hematology | Oncology
Oregon Oncology Specialists Llp
3025 Ryan Dr Se, 
Salem, OR 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Oregon Oncology Specialists Llp
3025 Ryan Dr Se, 
Salem, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Janelle Meyer is a Hematologist Oncology specialist and a Hematologist in Salem, Oregon. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Meyer is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Salem Health West Valley Hospital
Salem Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
ATRIO Health
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

OREGON ONCOLOGY SPECIALISTS LLP
3025 Ryan Dr Se, Salem, OR 97301
Call: 503-485-0350
Other Locations
OREGON ONCOLOGY SPECIALISTS LLP
875 Oak St Se, Suite 4030, Salem, OR 97301
Call: 503-561-6444
OREGON ONCOLOGY SPECIALISTS LLP
404 Welch St, Silverton, OR 97381
Call: 503-561-6444
OREGON ONCOLOGY SPECIALISTS LLP
1475 Mount Hood Ave, Woodburn, OR 97071
Call: 971-983-5210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: June 19, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Durvalumab, Olaparib
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Efatutazone
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drugs: Lerociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
View 6 Less Clinical Trials

2 Total Publications

Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Journal: Tomography (Ann Arbor, Mich.)
Published: January 10, 2017
View All 2 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Kevin W. Yee
Hematology | Hematology Oncology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Kevin W. Yee
Hematology | Hematology Oncology | Oncology

University Professional Services

15700 Sw Greystone Ct, 
Beaverton, OR 
 (41.8 miles away)
503-494-3442
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Yee is a Hematologist and a Hematologist Oncology provider in Beaverton, Oregon. Dr. Yee is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Yee is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Janet C. Ruzich
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Janet C. Ruzich
Hematology | Oncology
1500 Division Street, Suite 220, 
Oregon City, OR 
 (36.2 miles away)
503-513-1900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Janet Ruzich is a Hematologist and an Oncologist in Oregon City, Oregon. Dr. Ruzich is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Gallbladder Adenocarcinoma, Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Clear Cell Sarcoma. Dr. Ruzich is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Catherine A. O'brien
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Catherine A. O'brien
Hematology Oncology | Hematology | Oncology

Oregon Oncology Specialists Llp

2700 Se Stratus Ave, Suite A, 
Mcminnville, OR 
 (20.9 miles away)
503-435-6590
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Catherine O'brien is a Hematologist Oncology specialist and a Hematologist in Mcminnville, Oregon. Dr. O'brien is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Lung Cancer. Dr. O'brien is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meyer's expertise for a condition
ConditionClose
    • Distinguished
    • Breast Cancer
      Dr. Meyer is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Meyer is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Meyer is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Meyer is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Childhood Iron Deficiency Anemia
      Dr. Meyer is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Chronic Familial Neutropenia
      Dr. Meyer is
      Advanced
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    • Colorectal Cancer
      Dr. Meyer is
      Advanced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Dehydration
      Dr. Meyer is
      Advanced
      . Learn about Dehydration.
      See more Dehydration experts
    View All 15 Advanced Conditions
    • Experienced
    • Acute Mountain Sickness
      Dr. Meyer is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Meyer is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Meyer is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Meyer is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Promyelocytic Leukemia
      Dr. Meyer is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    • Adult Immune Thrombocytopenia
      Dr. Meyer is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved